Metformin has been the mainstay of diabetes treatment for 50 years with an impressive array of success stories in terms of effectiveness and affordability. On top of this, recent research points to the unexpected potential of metformin for the ability to reduce the risk of dementia and cancer and may even slow the aging process. So why is this drug so under-rated? Our review at metabolism.com digs into these intriguing questions.
A large percentage of physician policy makers in the U.S. are tied to pharmaceutical company interests through large sums of money they are paid as “consultants”.
New diabetes medications cost 100 times more than established treatments and are no more effective.
The FDA just announced its approval of linagliptin (Tradjenta), a new diabetes medication developed by Eli Lilly and Company and
New Diabetes Treatment Guidelines Lack Credibility: Recently the American Academy of Clinical Endocrinologists issued new treatment guidelines for treating Type